» Articles » PMID: 28338179

Effect of Dexmedetomidine on Immune Function of Patients Undergoing Radical Mastectomy: a Double Blind and Placebo Control Study

Overview
Date 2017 Mar 25
PMID 28338179
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To observe and evaluate the effect of dexmedetomidine on the perioperative immune function of patients undergoing a radical mastectomy.

Patients And Methods: 124 patients undergoing radical mastectomy were divided into the observation group (treated with dexmedetomidine) and the control group (treated with saline) by randomized digital table and double blinded and randomized design. 10 min before anesthesia induction, the patients in the observation group were injected with dexmedetomidine 0.1 ug.kg-1.min-1. The injection of 0.9% sodium chloride solution was given to the control group at the same rate. In the experiment, the medications of anesthesia induction and anesthesia maintain were identical. Venous blood at five times: T0 (before anesthesia), T1 (6 h after surgery), T2 (24 h after surgery), T3 (48 h after surgery), T4 (72 h after surgery) were collected. ELISA (Enzyme Linked Immunosorbent Assay) was used to detect concentrations of IL-2, IFN-γ, IL-4, IL-6 and IL-10; FACS flow cytometry was used to determine the level of T-lymphocyte subsets (CD3+, CD4+, CD8+) and NK cells.

Results: Compared with the control group, the cell levels of CD3+ and CD4+ in the observation group rose remarkably at T3 and T2 (p<0.05). The cell level of CD8+ fell at T2 with significant difference; NK cell level increased noticeably at T1 and T2, and CD4+/CD8+ rose dramatically at all postoperative time points. Obviously, the patients' immune function, to some extent, has been affected; in addition, the concentration of INF-γ in observation group increased prominently at T1, T2 and T3 (p<0.05), and the concentration of IL-2 at T2, IL-10 at T1 and T2, and IL-6 at T2 and T3 in the observation group all rose significantly (p<0.05), and less cytokine Th1 drifted to Th2.

Conclusions: The dexmedetomidine can effectively maintain the homeostasis of cell immune function of patients undergoing a radical mastectomy.

Citing Articles

Interventional factors influencing natural killer cell immunity in colorectal cancer: a systematic review.

Soh W, Burns G, Senanayake T, Cameron R, Duncanson K, Eslick G Cancer Immunol Immunother. 2025; 74(3):91.

PMID: 39891716 PMC: 11787105. DOI: 10.1007/s00262-024-03900-5.


Trial watch: dexmedetomidine in cancer therapy.

Carnet Le Provost K, Kepp O, Kroemer G, Bezu L Oncoimmunology. 2024; 13(1):2327143.

PMID: 38481729 PMC: 10936656. DOI: 10.1080/2162402X.2024.2327143.


Circulating biomarkers in perioperative management of cancer patients.

Huang Q, Zhou R, Hao X, Zhang W, Chen G, Zhu T Precis Clin Med. 2023; 6(3):pbad018.

PMID: 37954451 PMC: 10634636. DOI: 10.1093/pcmedi/pbad018.


Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model.

Jun J, Shim J, Oh J, Kim K, Kwak Y, Soh S Sci Rep. 2023; 13(1):12471.

PMID: 37528154 PMC: 10393998. DOI: 10.1038/s41598-023-39704-3.


Association between intraoperative dexmedetomidine and all-cause mortality and recurrence after laparoscopic resection of colorectal cancer: Follow-up analysis of a previous randomized controlled trial.

Hu J, Gong C, Xiao X, Chen L, Zhang Y, Li X Front Oncol. 2023; 13:906514.

PMID: 37064099 PMC: 10098183. DOI: 10.3389/fonc.2023.906514.